Skip to main content


COVID.virus_.corona.jpg (keep)

Rheum Drugs & IDSA Guidelines to Treat COVID-19

Dec 01, 2022

The Infectious Diseases Society of America has recently updated its recommendations with regards to the treatment of severely ill, hospitalized COVID-19 infected patients and also about the appropriate use of anti-IL-6, JAKs and colchicine.

Read Article

Low Dose IL-2 Therapy in Sjögren’s

Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article

Vaccine Efficacy in Patients with Seronegative Spondyloarthritis

Nov 14, 2022

Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.

Read Article
Do you know the 3 types of Y. Pestis plague? @AdamJBrownMD reviews the Bubonic, Pneumonic, and Septicemia plagues at #ACR22 @RheumNow. Most recently, there was an outbreak of Pneumonic plague in Madagascar in the 2010s!

Proposed Cancer Screening for Inflammatory Myositis Patients

Nov 12, 2022

Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer.  Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this

Read Article

Anifrolumab shows long-term promise in patients with lupus

Nov 12, 2022

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from

Read Article
infection pneumonia

Opportunistic Infections with JAK inhibitors in RA

Nov 07, 2022

Winthrop and colleagues have reviewd the occurrence of opportunistic infections (OIs) associated with the use of Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA), showing that Herpez zoster (HZ) was the most common OI reported with JAK inhibitors in clinical trials,

Read Article
RheumNow Podcast square

Women with Rheumatic Disease (11.4.2022)

Nov 04, 2022

Dr. Jack Cush reviews the news and journal articles from this past week on  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

  1. Population study shows among vaccinated gout pts, COVID breakthrough

Read Article
Efficacy of Shingrix Vaccine lasts for 10 yrs. Shingrix was approved in 2017 based on 2 Lg RCTs showing 6 yr. protective efficacy of 97% (ages>50) * 91% (age >70). Long-term F/U shows 81.6% effectfor mean of 9.6 (±0.3) years post-vaccination
RheumNow Podcast square

ACR Award Winners (10.21.2022)

Oct 21, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

  1. Vaccination Cut Long COVID Risk for Rheum Patients Patients with

Read Article

Prevotella Immune Response in Both Pre-Clinical & Established RA

EurekAlert! and Jack Cush
Oct 19, 2022

In a recent analysis published in Arthritis & Rheumatology, people at risk for rheumatoid arthritis (RA) and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). 

Read Article

CRTAC1- a Novel Biomarker for Osteoarthritis

Oct 17, 2022

Scientists at deCODE genetics a subsidiary of Amgen report in Arthritis & Rheumatology that a novel plasma protein (cartilage acidic protein-1; CRTAC1) is a potential biomarker of osteoarthritis (OA) through its association with OA risk and progression to joint replacement.

Read Article
RheumNow Podcast square

RheumNow Podcast – “That’s Not My Name” (10.7.2022)

Oct 07, 2022

Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on

  1. Microbiome analyses of

Read Article

IL-18 is a proinflammatory cytokine involved in innate &adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity

RheumNow Podcast square

Great and Not So Great (9.30.2022)

Sep 30, 2022

This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.

Read Article

2022 Lasker Award Winners

Sep 29, 2022

The Lasker Foundation has announced the winners of its 2022 Lasker Awards, widely regarded as America’s top biomedical research prize since its creation more than 75 years ago. Here's a look at the award winners and their important contributions to biomedical research.

Read Article

Immune Benefits to Sound Sleep

Sep 26, 2022

The revitalizing powers of sleep are numerous but what are the consequences to inadequate sleep? A current report in the Journal of Experimental Medicine shows the connection between sleep and immune function as measured in mice and humans; specifically, a good night’s sleep promotes normal

Read Article
RheumNow Podcast square

Heavy Metal Rheumatology (9.23.2022)

Sep 23, 2022

Below are this week’s highlights from RheumNow, as discussed by Dr. Jack Cush. Thanks to all of you for your kind comments and great reviews of our weekly podcast. Please let us know how we can improve by emailing me or recording your suggestion using the "Ask Cush Anything" link on our website

Read Article
antibody (Keep)

Clinical Profiles Seen with NXP-2 Antibodies

Sep 20, 2022

A recent review of the myositis associated autoantibody NXP-2 profiles its clinical associations with dermatomyositis (DM), calcinosis, severe myositis and, in some reports, with cancer.

Read Article
COVID infection mask

COVID Outcomes in Dermatomyositis

Sep 09, 2022

A retrospective study of dermatomyositis (DM) patients with COVID-19, shows that DM patients without comorbidities fair well (with regard to mortality and hospitalisation).

Read Article
RheumNow Podcast square

Does Fibromyalgia Need B12? (9.9.2022)

Sep 09, 2022

Can we predict the bad outcomes? Like when ITP evolves into SLE; or when psoriasis will develop arthritis; or if Sjogren's will develop lymphoma? Let's dive in and review these journal reports and this past week's news from

Read Article

Global Trends Informing the Future of Rheumatoid Arthritis

Sep 06, 2022

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 

The article appears in Nature Reviews Rheumatology and discusses worldwide variance

Read Article
RheumNow Podcast square

Goofy But True

Sep 02, 2022

Dr. Jack Cush discusses declining survival rates in the USA, FDA approvals of new COVID subvariant boosters and other odd and possibly true new research reports from the past week on

  1. After historic drop in 2020 (COVID), life expectancy in USA dropped again,

Read Article

Genetic Testing for Autoinflammatory Disease

Sep 01, 2022

Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as autoinflammatory diseases (AID) and some may be unclassifiable, clinically or genetically.

Read Article

Disease Activity Scoring in Adult-onset Still's disease

Aug 30, 2022

Still's disease in adults (AOSD) or children (sJIA) can have dramatic symptom severity, making it easy to gauge disease activity and response to therapy, especially at the outset. However, a validated measure of disease activity has not been agreed (for clinical trial and treatment assessments

Read Article